Clinical Trials

4 enrolled 8 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT07280494 2025-12-12

S101MRD

18 enrolled

Lymphoma, Neoplasm, Residual

NCT06649227 2025-12-05

CARLA-M19

Other hematologic neoplasm

5 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT03233854 2025-11-18

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

56 enrolled

Burkitt Lymphoma, Neoplasm, Residual

NCT07053670 2025-11-17

CT1190B

27 enrolled

Lymphoma, B-Cell

NCT07231081 2025-11-17

Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors

85 enrolled

Other solid neoplasm

Solid Tumors

NCT04007029 2025-09-05

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

24 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02917083 2025-07-25

RELY-30

60 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT04577326 2025-07-25

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Other solid neoplasmThoracic

14 enrolled

Mesothelioma, Malignant

NCT05225363 2025-07-01

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

33 enrolled

Gynecologic

Platinum-Resistant Ovarian Carcinoma

NCT03241940 2025-06-29

Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies

LymphoidOther hematologic neoplasm

33 enrolled

Burkitt Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07043218 2025-06-29

A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Phase 1 Not yet recruiting

36 enrolled

Burkitt Lymphoma

NCT06815029 2025-06-26

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

Phase 1 Not yet recruiting

27 enrolled

CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

NCT07032324 2025-06-23

CT1190B

27 enrolled

Lymphoma, B-Cell

NCT03186118 2025-06-17

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia